Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

te-release paclitaxel-eluting stent is not approved for commercial distribution.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com .

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.


    CONTACT:  Paul Donovan

              508-650-8541 (office)

              508-667-5165 (mobile)

              Media Relations

              Boston Scientific Corporation


              Dan Brennan

              508-650-8538 (office)

              617-459-2703 (mobile)

              Investor Relations

              Boston Scientific Corporation

Boston Scientific Corporation

CONTACT: Media Relations, Paul Donovan, +1-508-650-8541, mobile,+1-508-667-5165, Investor Relations, Dan Brennan, +1-508-650-8538, mobile,+1-617-459-2703, both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com/

Ticker Symbol: (NYSE:BSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ... per share, net to the seller in cash, without ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ... reductions in body fat content and preserved lean ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on ... results is scheduled for release after the close of ... Management will hold a conference call to discuss ... quarter and twelve months ended December 31, 2013 on ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... cancers and infectious diseases, announced today that Dr. J. Joseph ... the Cowen & Co. 31st Annual Health Care Conference being ... Boston, MA. Inovio Presentation: March 9, 2011 ...
... ALTO, Calif., Feb. 23, 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: ... make a presentation at the Citi 2011 Global Health Care ... 9:30 a.m. Eastern Time.  Bruce Cozadd, the company,s chairman and ... A live webcast of the presentation may be accessed from ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference 2Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... 30 Mylan Inc. (NYSE: MYL ),today announced ... and Global General Counsel. As Global General Counsel, Mr.,Haggerty ... provision of,legal services, counsel and advice globally to all ... the Company. Mr. Haggerty joins Mylan from Sanofi-Aventis ...
... MD, an associate professor of medicine at Boston University ... Internal Medicine Department at Boston Medical Center (BMC) and ... Treatment Division with the Boston Public Health Commission, was ... the Nyswander-Dole Award. The award was presented at the ...
... New research tracks the spread of HIV from Africa to ... into the genetic history of HIV suggests that the virus ... the last century, prior to reaching the United States. ... treatments for AIDS, but they could provide insight into how ...
... STE ) today announced financial results for its ... second quarter revenues,increased 4% to $295.0 million compared with ... driven by growth in the Healthcare and,Isomedix segments. ... or $0.25 per,diluted share, compared with net income of ...
... N.J., Oct. 30 Medarex, Inc.,(Nasdaq: MEDX ) ... the,JPMorgan Small/Mid Cap Conference in Boston on Monday, November ... be webcast live and will,be available for replay through ... Medarex website via the Internet at http://www.medarex.com . ...
... Symbol: CYT, MONTREAL, Oct. 30 /PRNewswire-FirstCall/ - ... cryotherapy products to treat cardiac,arrhythmias, today announced that ... at the 18th Annual CIBC Healthcare Conference at ... November 6. Mr. Keltjens will,present a corporate update, ...
Cached Medicine News:Health News:Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel 2Health News:AIDS Stopped in Haiti Before U.S. 2Health News:AIDS Stopped in Haiti Before U.S. 3Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 2Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 3Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 4Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 5Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 6Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 7Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 8Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 9Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath to present at CIBC Healthcare Conference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: